Vivani Medical, Inc. (VANI)
| Market Cap | 137.98M +84.8% |
| Revenue (ttm) | n/a |
| Net Income | -27.09M |
| EPS | -0.40 |
| Shares Out | 86.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,407,493 |
| Open | 1.360 |
| Previous Close | 1.350 |
| Day's Range | 1.330 - 1.580 |
| 52-Week Range | 0.923 - 1.920 |
| Beta | 3.29 |
| Analysts | Strong Buy |
| Price Target | 3.83 (+152.81%) |
| Earnings Date | Aug 12, 2026 |
About VANI
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutid... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for VANI stock is "Strong Buy." The 12-month stock price target is $3.83, which is an increase of 152.81% from the latest price.
News
Vivani Medical enters pact with Novo Nordisk to evaluate NPM-139
Vivani Medical (VANI) announced the signing of a new agreement with Novo Nordisk (NVO) to enable Novo Nordisk to evaluate NPM-139, the company’s semaglutide drug implant. NPM-139, which utilizes Vivan...
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug im...
Vivani Medical to merge Cortigent subsidiary with ClearOne
Vivani Medical (VANI) announced that it has entered into a definitive agreement and plan of merger among its wholly owned subsidiary Cortigent, ClearOne (CLRO) and a wholly owned subsidiary of…
ClearOne enters into merger agreement with Cortigent
ClearOne (CLRO) entered into a definitive agreement and plan of merger among its wholly-owned subsidiary, Vivani Medical (VANI), and Cortigent, a wholly-owned subsidiary of Vivani, pursuant to which C...
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (Nasdaq: CLRO), and change the listed company's name and ticker to Cortigent Holdings, Inc. (d/b/a Cortigent) ...
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical
SALT LAKE CITY--(BUSINESS WIRE)--ClearOne, Inc. (Nasdaq: CLRO) (“ClearOne”) announced today that it has entered into a definitive agreement and plan of merger (the “Agreement”) among its wholly-owned ...
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting d...
Vivani receives approval from Bellberry to initiate SLIM-1 trial in Australia
Vivani Medical (VANI) announced that it has received approval from Bellberry, a human research ethics committee, or HREC, in Australia to initiate SLIM-1, a Phase 1 clinical trial of NPM-139,…
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
ALAMEDA, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting d...
Vivani Medical initiated with a Buy at Lake Street
Lake Street initiated coverage of Vivani Medical (VANI) with a Buy rating and $4 price target One of the potential unmet needs in the weight management market is a longer-acting…
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...
Vivani Medical director buys $2.0M in common stock
In a regulatory filing, Vivani Medical (VANI) disclosed that its director Gregg Williams bought 1.59M shares of common stock on June 15th in a total transaction size of $2.0M. Shares…
Vivani Medical Transcript: Jefferies Global Healthcare Conference 2026
A novel GLP-1 implant aims to address poor adherence and tolerability in obesity treatment by providing steady, long-term drug delivery. Clinical trials for a semaglutide implant are set to begin, with promising preclinical results and strong patient interest supporting commercial potential.
Vivani Medical Slides: FY 2026
Vivani Medical has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 4, 2026.
Vivani Medical Slides: Corporate presentation
Vivani Medical has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivalent...
Vivani Medical Quarterly report: Q1 2026
Vivani Medical has published its Q1 2026 quarterly earnings report on May 13, 2026.
Vivani Medical Earnings release: Q1 2026
Vivani Medical released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Vivani Medical Proxy statement: Proxy filing
Vivani Medical filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Vivani Medical price target lowered to $3.50 from $4 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Vivani Medical (VANI) to $3.50 from $4 and keeps a Buy rating on the shares after the company recently…
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under...
Vivani Medical Earnings release: Q4 2025
Vivani Medical released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Vivani Medical Annual report: Q4 2025
Vivani Medical has published its Q4 2025 annual report on March 26, 2026.
Vivani’s Cortigent presents 6-year results for Orion system at NANS 2026
Vivani Medical (VANI) announced that Cortigent, its wholly-owned subsidiary developing brain implant devices, presented the results of a 6-year Early Feasibility Study of the Orion Visual Cortical Pro...
Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to have obtained FDA approval of a device providing artificial v...